Serelaxin improves the pathophysiology of placental ischemia in the reduced uterine perfusion pressure rat model of preeclampsia

American Journal of Physiology - Regulatory Integrative and Comparative Physiology

Volumn 311, Issue 6, 2016, Pages R1158-R1163

  Santiago Font, Jose A ^a   Amaral, Lorena M ^a   Faulkner, Jessica ^a   Ibrahim, Tarek ^a   Vaka, Venkata Ramana ^a   Cunningham, Mark W ^a   Lamarca, Babbette ^a  

^a UNIVERSITY OF MISSISSIPPI SCHOOL OF MEDICINE   (United States)

Author keywords

Dilation; Hypertension; Inflammation; Pregnancy

Indexed keywords

ENDOTHELIN 1; NITRATE; NITRIC OXIDE; NITRITE; PROTEIN TYROSINE KINASE; SERELAXIN; TUMOR NECROSIS FACTOR; RECOMBINANT PROTEIN; RELAXIN; SERELAXIN PROTEIN, HUMAN;

ANIMAL MODEL; ARTERY RESISTANCE; ARTICLE; BIOAVAILABILITY; BLOOD PRESSURE; CONTROLLED STUDY; FEMALE; GENE EXPRESSION; GESTATIONAL AGE; INTRAUTERINE PRESSURE; ISCHEMIA; KIDNEY CORTEX; MEAN ARTERIAL PRESSURE; NONHUMAN; PATHOPHYSIOLOGY; PERFUSION PRESSURE; PLACENTA DISORDER; PREECLAMPSIA; PRIORITY JOURNAL; RAT; UTERINE ARTERY; ANIMAL; BLOOD FLOW VELOCITY; DOSE RESPONSE; DRUG EFFECTS; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; SPRAGUE DAWLEY RAT; VASCULAR RESISTANCE; VASCULARIZATION;

ANIMALS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; ISCHEMIA; PLACENTA; PRE-ECLAMPSIA; PREGNANCY; RATS; RATS, SPRAGUE-DAWLEY; RECOMBINANT PROTEINS; RELAXIN; UTERINE ARTERY; VASCULAR RESISTANCE;

EID: 85002861348     PISSN: 03636119     EISSN: 15221490     Source Type: Journal    
DOI: 10.1152/ajpregu.00192.2016     Document Type: Article

References (33)

1. Amaral LM, Cornelius DC, Harmon A, Moseley J, Martin JN Jr, LaMarca B. 17-hydroxyprogesterone caproate significantly improves clinical characteristics of preeclampsia in the reduced uterine perfusion pressure rat model. Hypertension 65: 225–231, 2015. doi:10.1161/HYPERTENSIONAHA.114.04484.
2. Brewer J, Liu R, Lu Y, Scott J, Wallace K, Wallukat G, Moseley J, Herse F, Dechend R, Martin JN Jr, Lamarca B. Endothelin-1, oxidative stress, and endogenous angiotensin II: mechanisms of angiotensin II type I receptor autoantibody-enhanced renal and blood pressure response during pregnancy. Hypertension 62: 886–892, 2013. doi:10.1161/HYPERTENSIONAHA.113.01648.
3. Conrad KP. Emerging role of relaxin in the maternal adaptations to normal pregnancy: implications for preeclampsia. Semin Nephrol 31: 15–32, 2011. doi:10.1016/j.semnephrol.2010.10.003.
4. Conrad KP, Benyo DF. Placental cytokines and the pathogenesis of preeclampsia. Am J Reprod Immunol 37: 240–249, 1997. doi:10.1111/j.1600-0897.1997.tb00222.x.
5. Danielson LA, Sherwood OD, Conrad KP. Relaxin is a potent renal vasodilator in conscious rats. J Clin Invest 103: 525–533, 1999. doi: 10.1172/JCI5630.
6. Debrah DO, Novak J, Matthews JE, Ramirez RJ, Shroff SG, Conrad KP. Relaxin is essential for systemic vasodilation and increased global arterial compliance during early pregnancy in conscious rats. Endocrinology 147: 5126–5131, 2006. doi:10.1210/en.2006-0567.
7. Dechend R, Gratze P, Wallukat G, Shagdarsuren E, Plehm R, Bräsen JH, Fiebeler A, Schneider W, Caluwaerts S, Vercruysse L, Pijnenborg R, Luft FC, Müller DN. Agonistic autoantibodies to the AT1 receptor in a transgenic rat model of preeclampsia. Hypertension 45: 742–746, 2005. doi:10.1161/01.HYP.0000154785.50570.63.
8. Gilbert JS, Ryan MJ, LaMarca BB, Sedeek M, Murphy SR, Granger JP. Pathophysiology of hypertension during preeclampsia: linking placental ischemia with endothelial dysfunction. Am J Physiol Heart Circ Physiol 294: H541–H550, 2008. doi:10.1152/ajpheart.01113.2007.
9. Granger JP. Inflammatory cytokines, vascular function, and hypertension. Am J Physiol Regul Integr Comp Physiol 286: R989–R990, 2004. doi:10.1152/ajpregu.00157.2004.
10. Granger JP, Alexander BT, Llinas MT, Bennett WA, Khalil RA. Pathophysiology of hypertension during preeclampsia linking placental ischemia with endothelial dysfunction. Hypertension 38: 718–722, 2001. doi:10.1161/01.HYP.38.3.718.
11. Harmon A, Cornelius D, Amaral L, Paige A, Herse F, Ibrahim T, Wallukat G, Faulkner J, Moseley J, Dechend R, LaMarca B. IL-10 supplementation increases Tregs and decreases hypertension in the RUPP rat model of preeclampsia. Hypertens Pregnancy 34: 291–306, 2015. doi:10.3109/10641955.2015.1032054.
12. Herse F, LaMarca B. Angiotensin II type 1 receptor autoantibody (AT1-AA)-mediated pregnancy hypertension. Am J Reprod Immunol 69: 413–418, 2013. doi:10.1111/aji.12072.
13. Lamarca B. The role of immune activation in contributing to vascular dysfunction and the pathophysiology of hypertension during preeclampsia. Minerva Ginecol 62: 105–120, 2010.
14. LaMarca B, Wallace K, Herse F, Wallukat G, Martin JN Jr, Weimer A, Dechend R. Hypertension in response to placental ischemia during pregnancy: role of B lymphocytes. Hypertension 57: 865–871, 2011. doi:10.1161/HYPERTENSIONAHA.110.167569.
15. LaMarca BB, Cockrell K, Sullivan E, Bennett W, Granger JP. Role of endothelin in mediating tumor necrosis factor-induced hypertension in pregnant rats. Hypertension 46: 82–86, 2005. doi:10.1161/01.HYP.0000169152.59854.36.
16. Matsubara K, Matsubara Y, Hyodo S, Katayama T, Ito M. Role of nitric oxide and reactive oxygen species in the pathogenesis of preeclampsia. J Obstet Gynaecol Res 36: 239–247, 2010. doi:10.1111/j.1447-0756.2009.01128.x.
17. Molnár M, Sütö T, Tóth T, Hertelendy F. Prolonged blockade of nitric oxide synthesis in gravid rats produces sustained hypertension, proteinuria, thrombocytopenia, and intrauterine growth retardation. Am J Obstet Gynecol 170: 1458–1466, 1994. doi:10.1016/S0002-9378(13)90488-9.
18. Moncada S, Higgs A. The L-arginine-nitric oxide pathway. N Engl J Med 329: 2002–2012, 1993. doi:10.1056/NEJM199312303292706.
19. Murphy SR, LaMarca B, Cockrell K, Arany M, Granger JP. L-arginine supplementation abolishes the blood pressure and endothelin response to chronic increases in plasma sFlt-1 in pregnant rats. Am J Physiol Regul Integr Comp Physiol 302: R259–R263, 2012. doi: 10.1152/ajpregu.00319.2011.
20. Mutlu-Türkoglu U, Aykaç-Toker G, Ibrahimoglu L, Ademoglu E, Uysal M. Plasma nitric oxide metabolites and lipid peroxide levels in preeclamptic pregnant women before and after delivery. Gynecol Obstet Invest 48: 247–250, 1999. doi:10.1159/000010192.
21. Neri I, Mazza V, Galassi MC, Volpe A, Facchinetti F. Effects of L-arginine on utero-placental circulation in growth-retarded fetuses. Acta Obstet Gynecol Scand 75: 208–212, 1996. doi:10.3109/00016349609047088.
22. Noris M, Perico N, Remuzzi G. Mechanisms of disease: Pre-eclampsia. Nat Clin Pract Nephrol 1: 98–114, 2005. doi:10.1038/ncpneph0035.
23. Novak J, Danielson LA, Kerchner LJ, Sherwood OD, Ramirez RJ, Moalli PA, Conrad KP. Relaxin is essential for renal vasodilation during pregnancy in conscious rats. J Clin Invest 107: 1469–1475, 2001. doi: 10.1172/JCI11975.
24. Novotny S, Wallace K, Herse F, Moseley J, Darby M, Heath J, Gill J, Wallukat G, Martin JN, Dechend R, LaMarca B. CD4(+) T cells play a critical role in mediating hypertension in response to placental ischemia. J Hypertens (Los Angel) 2: pii: 14873, 2013.
25. Redman CW, Sargent IL. Latest advances in understanding preeclampsia. Science 308: 1592–1594, 2005. doi:10.1126/science.1111726.
26. Roberts JM, Pearson GD, Cutler JA, Lindheimer MD; National Heart Lung and Blood Institute. Summary of the NHLBI Working Group on Research on Hypertension During Pregnancy. Hypertens Pregnancy 22: 109–127, 2003. doi:10.1081/PRG-120016792.
27. Sandrim VC, Montenegro MF, Palei AC, Metzger IF, Sertorio JT, Cavalli RC, Tanus-Santos JE. Increased circulating cell-free hemoglobin levels reduce nitric oxide bioavailability in preeclampsia. Free Radic Biol Med 49: 493–500, 2010. doi:10.1016/j.freeradbiomed.2010.05.012.
28. Sankaralingam S, Arenas IA, Lalu MM, Davidge ST. Preeclampsia: current understanding of the molecular basis of vascular dysfunction. Expert Rev Mol Med 8: 1–20, 2006. doi:10.1017/S1462399406010465.
29. Sasser JM. The emerging role of relaxin as a novel therapeutic pathway in the treatment of chronic kidney disease. Am J Physiol Regul Integr Comp Physiol 305: R559–R565, 2013. doi:10.1152/ajpregu.00528.2012.
30. Sasser JM, Molnar M, Baylis C. Relaxin ameliorates hypertension and increases nitric oxide metabolite excretion in angiotensin II but not N(+)-nitro-L-arginine methyl ester hypertensive rats. Hypertension 58: 197–204, 2011. doi:10.1161/HYPERTENSIONAHA.110.164392.
31. Sibai B, Dekker G, Kupferminc M. Pre-eclampsia. Lancet 365: 785–799, 2005. doi:10.1016/S0140-6736(05)71003-5.
32. Tam Tam KB, George E, Cockrell K, Arany M, Speed J, Martin JN, Jr., Lamarca B, and Granger JP. Endothelin type A receptor antagonist attenuates placental ischemia-induced hypertension and uterine vascular resistance. Am J Obstet Gynecol 204: 330 e331–e334, 2011.
33. Wallukat G, Homuth V, Fischer T, Lindschau C, Horstkamp B, Jüpner A, Baur E, Nissen E, Vetter K, Neichel D, Dudenhausen JW, Haller H, Luft FC. Patients with preeclampsia develop agonistic autoantibodies against the angiotensin AT1 receptor. J Clin Invest 103: 945–952, 1999. doi:10.1172/JCI4106.